Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
PCVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.66 - $121.06
Previous CloseN/A
Volume105.48K
Average Volume (3M)3.21M
Market Cap
$3.77B
Enterprise Value$8.55B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 12, 2025EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding128,999,340
10 Day Avg. Volume2,096,230
30 Day Avg. Volume3,213,997
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-18.62
Forecast
1Y Price Target
$117.88Price Target Upside274.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Vaxcyte News
PremiumCompany Announcements
Vaxcyte, Inc. Reports Q1 2025 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial PotentialThe totality of data from VAX-24's Ph2 infant study offers a credible roadmap for Ph3 dosing, indicating potential improvements.
Competitive PositioningAnalysts reiterate Buy on PCVX’s underappreciated competitive positioning in the huge $8b+ PCV category.
Pipeline InnovationThe newly announced VAX-XL was highlighted, indicating ongoing innovation and expansion in Vaxcyte's pipeline.
Bears Say
Clinical Trial ChallengesThe VAX-24 infant study missed post-dose 3 primary serotype conversion rate non-inferiority criteria on 4 of 24 serotypes relative to Prevnar 20.
Disappointing DataFollowing PCVX’s disappointing Ph2 VAX-24 infant data, the price target is reduced from $153 to $65.
Regulatory ChallengesAnti-vaccine news flow and regulatory uncertainty out of HHS/FDA, including this week's appointment of Dr. Vinay Prasad as head of CBER, continue to put pressure on shares.
---
Ownership Overview
0.93% Insiders
43.60% Mutual Funds
0.32% Other Institutional Investors
38.85% Public Companies and
Individual Investors
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $27.66 and its highest was $121.06 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $3.77B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 94 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on May 07, 2025. The company reported -$1.04 earnings per share for the quarter, beating the consensus estimate of -$1.061 by $0.021.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.18.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 128,999,340 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.04 in its last earnings report, beating expectations of -$1.061. Following the earnings report the stock price went up 8.448%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
---
Vaxcyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.88 (274.82% Upside)
$117.88 (274.82% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 605.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.96%
12-Months-Change
Fundamentals
Return on Equity
-19.66%
Trailing 12-Months
Asset Growth
150.96%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
---
PCVX Company Deck
---
PCVX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Vaxcyte's strong financial position, significant clinical and manufacturing progress, and proactive regulatory engagement. However, challenges include increased expenses, potential regulatory uncertainties, and the need to meet non-inferiority criteria in clinical studies. Vaxcyte remains optimistic about its pipeline and future growth.Read More>---
PCVX Stock 12 Month Forecast
Average Price Target
$117.88
▲(274.82% Upside)
Technical Analysis
---